Follow the analysis back to the evidence
Choose an initiation close to your company’s sector and stage. A useful sample will show how demand translates into revenue, how much the company needs to spend to deliver, and what could cause the valuation to change. Review a few important figures and trace them to the filing, technical disclosure, or forecast assumption behind them. A strong report will tell you where the analyst relies on public evidence and where the model necessarily uses judgment.
Read the risks with the forecast open. If a critical risk is delayed approval, look for the effect of a later launch on trial spending, cash runway, and the period during which the product could earn revenue. If the issue is customer concentration, see whether the report addresses contract terms, renewal exposure, and the margin effect of losing a large account. A risk section that has little connection to the forecast is difficult to use.
The Helus Pharma initiation and November update are one published example of how AER establishes a clinical and financial framework and revisits it as developments occur. Both publications identify their research classification.
Meet the analyst who will do the work
Credentials provide context. The conversation should also establish that the responsible analyst understands your company’s sources of uncertainty. Ask them how they would interpret a recent earnings release, trial result, or operational change based on public information. Gauge whether they can distinguish an accounting movement from a change in operating performance and identify which assumptions would need further work.
Ask who builds and owns the model, who reviews it for consistency with the report, and who will cover the company after initiation. Coverage continuity becomes important when material events overlap with reporting season. Find out whether the firm has a responsible backup analyst and how it hands over source notes and assumptions if the lead changes.
Examine a model the way an investor would
Ask to see a public or appropriately redacted model. Start with the outputs an investor might scrutinize, such as free cash flow, runway, return on invested capital, or value per share. Work back to the schedules feeding those outputs. You should be able to identify the material operating assumptions, the periods supported by actuals, and the adjustments that reconcile the forecast with the company’s reporting.
A scenario should have an economic explanation. For example, a slower mining ramp can defer sales, increase cash costs per unit, and increase the funding required before the asset is self-sustaining. Changing three cells independently may miss those interactions. Ask how the provider organizes scenarios, documents changes after publication, and handles financing and dilution in the per-share valuation.
Review the model alongside its report date. Spot-check whether reported historical results reconcile, whether cash and debt link to the financial statements, and whether the share count used for valuation is current. Then inspect an update for the same company. An investor should be able to tell when a higher revenue estimate came from a change in assumptions rather than a presentation or reporting change.
Verify publication cadence and actual distribution
Ask for an example where the analyst had to reconsider a forecast after a material event. The update should explain which estimate changed, why the new evidence changed it, and what remained uncertain. Discuss how often the provider will cover earnings, how it decides when to issue an event note, and how it handles changes significant enough to revise the model.
Map distribution to the actual readers you want to reach. Ask which named channels are active, which are being set up, and what they can carry. A platform listing may give subscribers a report without a downloadable model. Request a sample public link and, where available, evidence that a report appears in the institutional channel described. For media and newswire distribution, confirm what will be submitted and which placements depend on third-party acceptance.
Read the engagement terms before making the decision
A proposal should state who controls the draft, how any factual review works, and what happens when management disagrees with a forecast. Ask where sponsorship will appear in the report and whether the provider’s disclosures follow each distribution format. In the United States, Securities Act Section 17(b) sets disclosure requirements for covered paid communications. For EU distribution, questions about contract length, payment, review, and labeling may depend on the EU code.
Compare scope, renewal, fee schedule, model access, and publication rights in the written proposal. Review the process for adding a newly acquired business or a development program that materially increases the work. Clarify how long existing reports remain available and how readers will understand that coverage has ended. A provider that can describe exactly what it will deliver makes it easier to assess the cost of the mandate.
Frequently asked questions
Should we ask for a sample on a company in the same sector?
Yes, where possible. If a close peer is unavailable, look for a business with similar modeling challenges, such as a development-stage asset, complex reimbursement, or a project that needs external funding.
What if the provider cannot share a client workbook?
Ask for a public or redacted example and a walkthrough of its material schedules. Confirm what readers and your team would be able to access under the proposed mandate.
Can we review forecasts before a provider publishes?
Agree the factual review procedure in advance, subject to applicable rules. The research provider should control forecasts and valuation. Certain regimes, including the EU code, restrict review of drafts containing recommendations or target prices.